Imunon, Inc. CLSN
At closeSep 21, 2022, 12:00 AM EDT
52-week range unavailable
- Market cap
- 13.91M
- Revenue (ttm)
- 500.00K
- Shares out
- 7.10M
- Forward P/E
- -0.52
- Volume
- 56.81K
- Open
- 1.96
- Previous close
- 1.95
- Day's range
- 1.93 – 1.99
- Beta
- 2.26
- Analysts
- Buy
- Price target
- 27.00 (+1287.0%)
- Earnings date
- Aug 15, 2022
2Y -10.76 (-84.59%)
Key statistics
- Enterprise value
- -21.74M
- PEG ratio
- 0.00
- Price / sales
- 27.83
- Price / book
- 0.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.92M
- Total cash
- 42.11M
- Total debt
- 6.46M
- Return on equity
- -47.08%
- Short % of float
- 0.79%
- 50-day average
- 2.20
- 200-day average
- 2.52
Analyst view
Consensus: buy
- Target (low)
- 16.00
- Target (mean)
- 27.00
- Target (high)
- 45.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 15, 2022
Expected Aug 15, 2022. Consensus EPS estimate -0.81.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 15, 2022 | Jun 1, 2022 | -1.12 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -1.01 | — | — | — |
| Mar 31, 2022 | Dec 1, 2021 | -0.90 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | -1.20 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -1.20 | — | — | — |
| May 14, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 13, 2022 | HC Wainwright & Co. | init | — | Buy |
| Nov 22, 2017 | Oppenheimer | init | — | Outperform |
| Oct 5, 2017 | Maxim Group | up | Hold | Buy |
| Jul 15, 2015 | Maxim Group | init | — | Buy |
| Jul 13, 2015 | BTIG Research | init | — | Buy |
| Sep 30, 2013 | H.C. Wainwright | init | — | Buy |
About Imunon, Inc.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celsion.com
News
Celsion Corporation Announces Company Name Change to Imunon, Inc. 
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer 
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. 
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference 
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program 
Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript 
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update 
Earnings Scheduled For August 15, 2022 
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022 
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
Your note
Sign in to keep a note on CLSN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORYS NICHOLAS | Officer | Stock Award(Grant) | Feb 1, 2016 | 19,926 |
| BRAUN DONALD P | Director | Purchase | May 16, 2021 | 5,357 |
| CHURCH JEFFREY WAYNE | Chief Financial Officer | Stock Award(Grant) | Feb 24, 2020 | 54,298 |
| FRITZ FREDERICK J | Director | Purchase | Apr 7, 2022 | 11,766 |
| HOOPER ROBERT W | Director | Purchase | Oct 2, 2018 | 25,687 |
| KARDARAS CONSTANTINE JOHN | Officer | Stock Award(Grant) | Dec 13, 2021 | 10,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Murchinson Ltd. | 3.90% | 276,644 | 542.22K | Jun 29, 2022 |
| Vanguard Group, Inc. (The) | 3.31% | 234,953 | 460.51K | Jun 29, 2022 |
| Two Sigma Advisers, LP | 1.61% | 114,304 | 224.03K | Jun 29, 2022 |
| Blackrock Inc. | 0.95% | 67,730 | 132.75K | Jun 29, 2022 |
| Susquehanna International Group, LLP | 0.74% | 52,274 | 102.46K | Jun 29, 2022 |
| Renaissance Technologies, LLC | 0.74% | 52,311 | 102.53K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.94% | 137,780 | 270.05K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 1.12% | 79,599 | 156.01K | Jun 29, 2022 |
| Fidelity Extended Market Index Fund | 0.42% | 29,987 | 58.77K | Jun 29, 2022 |
| iShares Micro Cap ETF | 0.18% | 12,780 | 25.05K | May 30, 2022 |
| Vanguard Balanced Index Fund | 0.13% | 9,191 | 18.01K | Jun 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.12% | 8,671 | 17.00K | Aug 30, 2022 |